Fajriah Azra
Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, 25131, Indonesia

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

DOCKING SIMULATION OF 1,2,3-TRIAZOLO-INDOLE-2-CARBOXYLATE DERIVATIVES AS POTENTIAL HER2 INHIBITORS FOR BREAST CANCER THERAPY Alia Rahman; Fajriah Azra
Jurnal Crystal : Publikasi Penelitian Kimia dan Terapannya Vol. 8 No. 2 (2026): Literasi Artikel Penelitian Kimia
Publisher : Program Studi Kimia, Fakultas MIPA, Universitas PGRI Banyuwangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36526/jc.v8i2.7201

Abstract

HER2 is a tyrosine kinase receptor involved in cell proliferation, differentiation, and survival. Its overexpression promotes cancer progression and therapeutic resistance, indicating the need for new HER2 inhibitors. In this study, twelve 1,2,3-triazolo-indole-2-carboxylate derivatives were evaluated as potential HER2 inhibitors using in silico approaches. Drug-likeness was analyzed using SwissADME, ADMET properties were predicted with pkCSM, and molecular docking was performed using MOE. Docking analysis indicated that several compounds exhibited strong binding affinity toward HER2, with compounds 6b, 6c, 6d, 6e, and 9a identified as the most promising candidates. Among them, compound 6d showed the most balanced profile, combining strong binding affinity, favorable interactions comparable to lapatinib, moderate aqueous solubility, high Caco-2 permeability, non-substrate behavior toward P-gp, and non-mutagenic properties. ADMET evaluation revealed that all compounds complied with Lipinski’s rule and exhibited high total clearance. However, limitations were observed in distribution parameters (VDss, Fu, and BBB), potential hepatotoxicity, and inhibition of several CYP enzymes, except CYP2D6. Overall, compound 6d is proposed as a promising HER2 inhibitor candidate, although further in vitro and in vivo validation is required to improve safety and pharmacokinetic profiles.
MOLECULAR DOCKING OF QUERCETIN DERIVATIVES AGAINST EGFR IN NON–SMALL CELL LUNG CANCER (NSCLC) Maylina Dwi Lestari; Fajriah Azra
Jurnal Crystal : Publikasi Penelitian Kimia dan Terapannya Vol. 8 No. 2 (2026): Literasi Artikel Penelitian Kimia
Publisher : Program Studi Kimia, Fakultas MIPA, Universitas PGRI Banyuwangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36526/jc.v8i2.7202

Abstract

Non – small cell lung cancer (NSCLC) is leading cause of cancer – related mortality. Resistance to existing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors remains a major therapeutic challenge. This study investigates the potential of thirteen 8 – heteroarylated quercetin derivatives as EGFR inhibitors using a structure – based molecular docking approach integrated with in silico ADMET prediction and drug – likeness assessment. Docking simulations were performed against EGFR (PDB ID: 4WKQ) using MOE 2022, with gefitinib serving as the reference ligand. ADMET evaluation was conducted using the pkCSM web server, while drug – likeness assessment was carried out using SwissADME. The docking results revealed that five compounds (2i, 2b, 2m, 2a, and 2c) exhibited more favorable binding affinity than the control and formed key hydrogen – bond interactions with resiude Met793, along with additional interactions within the ATP – binding site. ADMET and drug – likeness analyses predicted that most derivatives complied with Lipinski’s criteria, with compounds 2a and 2m demonstrating superior pharmacokinetic profiles, including higher solubility, acceptable intestinal permeability, low blood – brain barrier penetration, and low predicted acute toxicity and mutagenicity. Overall, these in silico findings identify compounds 2a and 2m as the most promising quercetin – based EGFR inhibitor candidates for futher development.
MOLEKULER DOCKING SENYAWA TURUNAN BENZIMIDAZOLE DENGAN PROTEIN TARGET EGFR SEBAGAI OBAT ANTI-KANKER PAYUDARA fadillah hakim; Fajriah Azra
Jurnal Crystal : Publikasi Penelitian Kimia dan Terapannya Vol. 8 No. 2 (2026): Literasi Artikel Penelitian Kimia
Publisher : Program Studi Kimia, Fakultas MIPA, Universitas PGRI Banyuwangi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36526/jc.v8i2.7203

Abstract

Kanker merupakan salah satu penyebab utama kematian di seluruh dunia. Di antara berbagai jenis kanker, kanker payudara menempati posisi yang sangat penting sebagai penyebab utama kematian pada wanita di seluruh dunia. Selain itu, Reseptor Faktor Pertumbuhan Epidermal (EGFR) juga dapat berperan dalam memicu perkembangan kanker payudara. Gugus benzimidazol memungkinkan berbagai pola substitusi pada tujuh posisi, yang memungkinkan bioaktivitas yang beragam dan unik dalam beberapa kelas obat. Senyawa ini memiliki banyak manfaat medis, termasuk antijamur, antikanker, antiulkus, antimikroba, antikoagulan, antivirus human cytomegalovirus (HCMV), antiinflamasi, dan penghambat HIV-1. Perkembangan teknologi telah memungkinkan pemodelan obat menggunakan metode in silico. Salah satu metode yang banyak digunakan adalah molecular docking, yaitu simulasi komputer untuk memprediksi interaksi ligan dengan reseptor target pada situs aktifnya. Hasil senyawa turunan benzimidazol 4d, 4e, dan 4i yang paling stabil diperoleh dan mencapai profil kelayakan ADMET terbaik. Pendekatan in silico yang digunakan dalam penelitian ini terbukti efektif untuk mempercepat seleksi senyawa turnan benzimidazole sebagai penentu (dice) untuk obat antikanker payudara.